In DepthBiomedicine

Antiaging trial using young blood stirs concerns

See allHide authors and affiliations

Science  05 Aug 2016:
Vol. 353, Issue 6299, pp. 527-528
DOI: 10.1126/science.353.6299.527

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The first-ever clinical trial in the United States to test the antiaging benefits of an unusual therapy—plasma from young donors—in relatively healthy people is getting underway this month. The trial was inspired in part by a 2014 study finding that injecting old mice with the plasma portion of blood from young mice seemed to improve the elderly rodents' memory and ability to learn. But there's a big caveat: The company, Ambrosia, plans to charge participants $8000 for lab tests and a one-time treatment. To some ethicists and researchers, the trial raises red flags, both for its cost to participants and for a design that they say is unlikely to deliver much science.